Hepatocellular Carcinoma: Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy (Adv. Sci. 5/2021)

Xu, Shengjun; Ling, Sunbin; Shan, Qiaonan; Ye, Qianwei; Zhan, Qifan; Jiang, Guangjiang; Zhuo, Jianyong; Pan, Bin; Wang, Xue; Feng, Tingting; Lu, Haohao; Wei, Xuyong; Xie, Haiyang; Zheng, Shusen; Xiang, Jiajia; Shen, Youqing; Xu, Xiao Chun

doi:10.1002/advs.202170022

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We first studied the synergetic effect of hemin and sorafenib on SMMC7721 cells using cytotoxicity assessment with four different weight ratios of sorafenib/hemin (1:0.125, 1:0.25, 1:0.5, and 1:1), and analyzed the combination index values (CI). [ 24 ] Obviously, hemin alone was almost nontoxic to HCC cells. However, when combined with sorafenib, hemin considerably enhanced the cytotoxicity of sorafenib (Figure S1, Supporting Information), In addition, the CI values were 0.832, 0.776, 0.778, and 0.508, respectively, for the four different weight ratios of sorafenib/hemin (1:0.125, 1:0.25, 1:0.5, and 1:1), highlighting a synergetic effect of sorafenib and hemin combination (Table S1, Supporting Information).…”

Section: Resultsmentioning

confidence: 99%

Amphiphilic Dendrimer Doping Enhanced pH‐Sensitivity of Liposomal Vesicle for Effective Co‐delivery toward Synergistic Ferroptosis–Apoptosis Therapy of Hepatocellular Carcinoma

Zhang

Lee

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Ferroptosis, characterized by the accumulation of reactive oxygen species and lipid peroxides, has emerged as an attractive strategy to reverse drug resistance. Of particular interest is the ferroptosis–apoptosis combination therapy for cancer treatment. Herein, a nanoplatform is reported for effective co‐delivery of the anticancer drug sorafenib (S) and the ferroptosis inducer hemin (H), toward synergistic ferroptosis–apoptosis therapy of advanced hepatocellular carcinoma (HCC) as a proof‐of‐concept study. Liposome is an excellent delivery system; however, it is not sufficiently responsive to the acidic tumor microenvironment (TME) for tumor‐targeted drug delivery. The pH‐sensitive vesicles are therefore developed (SH‐AD‐L) by incorporating amphiphilic dendrimers (AD) into liposomes for controlled and pH‐stimulated release of sorafenib and hemin in the acidic TME, thanks to the protonation of numerous amine functionalities in AD. Importantly, SH‐AD‐L not only blocked glutathione synthesis to disrupt the antioxidant system, but also increased intracellular Fe2+ and ·OH concentrations to amplify oxidative stress, both of which contribute to enhanced ferroptosis. Remarkably, high levels of ·OH also augmented sorafenib‐mediated apoptosis in tumor cells. This study demonstrates the efficacy of ferroptosis–apoptosis combination therapy, as well as the promise of the AD‐doped TME‐responsive vesicles for drug delivery in combination therapy to treat advanced HCC.

show abstract

Section: Resultsmentioning

confidence: 99%